Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Nov 28;11(11):e0167131. doi: 10.1371/journal.pone.0167131

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Bhattacharjee et al

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Fig 10 — Histological (Panel A) and ultrastructural (Panel B) assessments of heart of T2D rats of different groups. Group II exhibited degeneration of interstitial tissues (blue arrows) and change in normal radiating pattern (yellow arrows) in the section of heart, while, Group I exhibited general radiating pattern of heart section. SEM showed ventricular portion of araldite sectioned rat myocardial tissues. Myocardial tissue of normal rats (Group I) exhibited normal myocardial fine structure, with myofibrils comprising regular and continuous sarcomeres which demarcated by Z-lines (Red arrow heads), which were in register with adjacent myofibrils and the rows of moderately electron dense mitochondria (Mi) intervene between myofibrils, while, Group II showed randomly distributed mitochondria (Mi) between poorly organized myofibrils in an electron-lucent sarcoplasm. Group III, IV and V indicated significant improvement in myofibrillar arrangement in heart tissues comparable to that of Group I. Group I: Normal control; Group II: T2D control; Group III: T2D rats treated with SR (50 mg/kg, orally); Group IV: T2D rats treated with SR (100 mg/kg, orally); Group V: T2D rats treated with glibenclamide (1 mg/kg, orally).